BioSpace News Archive

The new research hub will be called the London Discovery Research Centre and is expected to open by 2025.

The legal ruling, subject to appeal, protects the Swiss pharma giant’s revenue stream from the blockbuster drug Gilenya for a little bit longer.

Despite the urgent need for more research into the coronavirus, the New York Times reported on August 14 that there have been numerous testing delays, staffing shortages and space constraints tying up the process.

Shares of Poseida Therapeutics plunged more than 20% in premarket trading this morning after the company announced the U.S. Food and Drug Administration halted a cancer drug trial due to safety concerns.

Together the two companies will scour comprehensive medical and molecular data sets of thousands of chronic kidney disease patients to identify and then develop possible drugs.

“Joining the board will allow me to help guide and influence the development of a product from bench to bedside,” Franchimont told BioSpace. “I look forward to contributing to ongoing discussions on translation from bench science to the clinic, and ultimately to making real differences in the lives of patients.”

Eli Lilly will aim a checkpoint inhibitor it co-developed for the Chinese market at the United States and other western markets.

Shortly before COVID-19 patients’ conditions advance from moderate to severe, their levels of type I interferon (IFN) are present in the bloodstream drop.

A study published in JAMA Cardiology back on July 27 is now raising concern in the medical community, as many coronavirus patients are exhibiting signs of heart damage, despite being asymptomatic.

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the closing of its previously announced underwritten public offering of 5,000,000 shares of common stock at a public offering price of $7.00 per share. The aggregate gross proceeds to Equillium from this offering, before deducting underwriting discounts and commissions and other offe